SCHEMBL752358

SCHEMBL752358

Cc1n[c]cc(NC(=O)Cc2cccc(F)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 1/20 0.50
PRKACA P17612 1/20 0.46
ROCK1 Q13464 1/20 0.46
GLS O94925 3/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPK8 P45983 1/20 0.45
ANO1 Q5XXA6 1/20 0.44
KCNQ2 O43526 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.41
ROCK2 O75116 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750914 0.84 ALDH1A1 (0.56) PRKACAROCK1GLSMEN1KMT2A
SCHEMBL752493 0.81 MAPK8 (0.45) NPC1RAB9AMAPK8SMN1; SMN2
SCHEMBL750723 0.71 ABCG2 (0.49) L3MBTL1MAPTMEN1KMT2ANPC1
SCHEMBL764190 0.71 ABL1 (0.39) L3MBTL1MAPTMEN1KMT2AADORA1
SCHEMBL3421534 0.71 GLS (0.50) L3MBTL1MAPTPRKACAROCK1GLS
SCHEMBL13329762 0.70 SRC (0.52) L3MBTL1MAPTPRKACAROCK1GLS
SCHEMBL31240637 0.69 RIOK2 (0.66) PRKACAROCK1GLSMEN1KMT2A
SCHEMBL8269640 0.68 KMT2A (0.64) L3MBTL1MAPTMEN1KMT2ANPC1
SCHEMBL21980987 0.68 SRC (0.54) L3MBTL1MAPTGLSMEN1KMT2A
SCHEMBL18766915 0.68 SRC (0.57) L3MBTL1MAPTGLSMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD L3MBTL1 4014/4885MAPT 3169/4885PRKACA 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.